Patents by Inventor Cécile Schiffer-Mannioui

Cécile Schiffer-Mannioui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11987639
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: May 21, 2024
    Inventor: Cecile Schiffer-Mannioui
  • Patent number: 11690873
    Abstract: The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: July 4, 2023
    Assignee: CELLECTIS SA
    Inventors: Cecile Schiffer-Mannioui, Philippe Duchateau, Anne-Sophie Gautron
  • Publication number: 20230201260
    Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Application
    Filed: November 17, 2022
    Publication date: June 29, 2023
    Applicant: CELLECTIS
    Inventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cécile SCHIFFER-MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
  • Publication number: 20230068949
    Abstract: The present invention relates to engineered immune cells expressing new mesothelin (MLSN) specific chimeric antigen receptors (anti-mesothelin CAR) and their use in the treatment of solid tumors, particularly suited for allogeneic cell immunotherapy.
    Type: Application
    Filed: December 22, 2020
    Publication date: March 2, 2023
    Inventors: Cecile SCHIFFER-MANNIOUI, Philippe DUCHATEAU
  • Publication number: 20230056268
    Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to highly efficient adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Application
    Filed: April 8, 2022
    Publication date: February 23, 2023
    Applicant: CELLECTIS
    Inventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cécile SCHIFFER-MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
  • Publication number: 20230050345
    Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Application
    Filed: April 7, 2022
    Publication date: February 16, 2023
    Applicant: CELLECTIS
    Inventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cécile SCHIFFER-MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
  • Patent number: 11311575
    Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to highly efficient adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: April 26, 2022
    Assignee: CELLECTIS
    Inventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
  • Patent number: 11304975
    Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: April 19, 2022
    Assignee: CELLECTIS
    Inventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
  • Patent number: 11077144
    Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: August 3, 2021
    Assignee: Cellectis
    Inventors: Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
  • Patent number: 11007224
    Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: May 18, 2021
    Assignee: Cellectis
    Inventors: Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
  • Publication number: 20210100839
    Abstract: The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.
    Type: Application
    Filed: March 30, 2018
    Publication date: April 8, 2021
    Inventors: Cecile Schiffer-Mannioui, Philippe Duchateau, Anne-Sophie Gautron
  • Publication number: 20210060079
    Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 4, 2021
    Inventors: Roman GALETTO, Julianne SMITH, Andrew SCHARENBERG, Cécile SCHIFFER-MANNIOUI
  • Publication number: 20210060080
    Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 4, 2021
    Inventors: Roman GALETTO, Julianne SMITH, Andrew SCHARENBERG, Cécile SCHIFFER-MANNIOUI
  • Publication number: 20210000869
    Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells; expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.
    Type: Application
    Filed: March 26, 2019
    Publication date: January 7, 2021
    Inventors: Roman Galetto, Julianne SMITH, Andrew SCHARENBERG, Cecile SCHIFFER-MANNIOUI
  • Publication number: 20200407461
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.
    Type: Application
    Filed: July 24, 2020
    Publication date: December 31, 2020
    Inventor: Cecile Schiffer-Mannioui
  • Patent number: 10874693
    Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: December 29, 2020
    Assignee: Cellectis
    Inventors: Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
  • Patent number: 10759868
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: September 1, 2020
    Assignee: CELLECTIS
    Inventor: Cècile Schiffer-Mannioui
  • Patent number: 10752684
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a ROR1 monoclonal antibody, conferring specific immunity against ROR1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as breast, colon, lung, and kidney tumors.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: August 25, 2020
    Assignee: CELLECTIS
    Inventor: Cècile Schiffer-Mannioui
  • Patent number: 10752670
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a GD3 monoclonal antibody, conferring specific immunity against GD3 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating solid tumors such as melanomas, carcinomas or liquid tumor such as T-cell lymphoblastic leukemia.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: August 25, 2020
    Assignee: CELLECTIS
    Inventors: Julianne Smith, Cècile Schiffer-Mannioui
  • Patent number: 10544201
    Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen ROR1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen ROR1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially chronic lymphocytic leukemia or solid tumors.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: January 28, 2020
    Assignee: CELLECTIS
    Inventor: Cècile Schiffer-Mannioui